Annual vaccinations reduced the number of hospitalisations in children by 50%, not only...
NIAID launches infectious diseases clinical research consortium
National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has established the infectious diseases clinical research consortium.
GSK Phase III trial of Benlysta shows improvement in SLE patients
GlaxoSmithKline (GSK) has reported that a controlled Phase III BLISS-LN clinical trial of Benlysta (belimumab) showed improvements in systemic lupus erythematosus (SLE) patients.
Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
riginally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin formulated with Sodium N-[8-(2-hydroxy benzoyl) amino] caprylate (SNAC).
Griffith University-led research projects secure funding from NHMRC
Griffith University-led research projects have received funding from the National Health and Medical Research Council (NHMRC).
FDA and NCATS launch CURE ID app for healthcare professionals
The US Food and Drug Administration (FDA) and the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) have launched a new app called CURE ID for health care professionals.
Valneva chikungunya vaccine shows promise in Phase I trial
French biotech company Valneva has announced positive data from the Phase I clinical trial of its chikungunya vaccine candidate, VLA1553.
VBI Vaccines and Brii Biosciences launch trial to treat HBV infection
VBI Vaccines and Brii Biosciences have initiated a Phase Ib/IIa clinical trial to test BRII-179 (VBI-2601) for the treatment of patients with chronic hepatitis B virus (HBV) infection.
Bavarian Nordic reports Phase III data for smallpox vaccine
Bavarian Nordic has reported data from the Phase III efficacy study of MVA-BN (Jynneos) vaccine, which is designed to prevent smallpox and monkeypox disease in adults aged above 18 years.
Gilead’s Biktarvy shows high virologic suppression in HIV patients
Gilead Sciences has reported positive three-year data from two Phase III clinical trials of Biktarvy in adults with human immunodeficiency virus-1 (HIV-1) infection.